Stock Analiz

AC Immune SA ACIU

Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026

$2.13Market cap $217M
Open the interactive analysis →

AC Immune SA (ACIU) is a healthcare company listed in the US with a market value of about $217M. In fiscal year 2025 it had revenue of $5M and net income of -$89M, a net margin of -1971.6%.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -24% a year, a 5-year average ROIC of -56%.

About AC Immune SA

AC Immune SA is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. Revenue went from $39M in 2015 to $5M in 2025, a decline of about 19.5% a year. It was profitable in 1 of the last 10 years in our data.

Score: 0.2 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E3.1
P/FCF—
P/S9.2
P/B6.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-40.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-85.0%
Revenue growth (5 yrs, per year)-23.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1080.6%
ROIC (5-yr avg.)-55.5%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$5M$30M$18M$4M$0$18M$114M$7M$21M$23M
Net income-$89M-$56M-$65M-$77M-$80M-$70M$47M-$52M-$27M-$7M
Free cash flow-$89M$72M-$73M-$81M-$75M-$70M$55M-$47M-$24M-$6M
EPS (diluted)$-0.87$-0.55$-0.64$-0.75$-0.79$-0.69$0.46$-0.51$-0.27$-0.07
Net margin-1971.7%-186.4%-366.4%-1798.0%—-401.3%41.1%-737.1%-130.4%-30.6%
ROIC-154.4%-36.9%-26.4%-33.1%-26.9%-28.4%16.4%-27.9%-19.3%-7.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does AC Immune SA pay a dividend?

Not currently.

Is AC Immune SA a good stock to buy?

We do not give buy or sell advice. AC Immune SA scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.